Cargando…

复发性小细胞肺癌治疗进展

Small cell lung cancer (SCLC) is a highly malignant tumor. The initial treatment of radiotherapy and chemotherapy are more sensitive, high remission rate, but susceptible to drug resistance and relapse after treatment. Although the treatment of lung cancer has undergone enormous changes in recent ye...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973303/
https://www.ncbi.nlm.nih.gov/pubmed/28302222
http://dx.doi.org/10.3779/j.issn.1009-3419.2017.03.08
_version_ 1783326590521835520
collection PubMed
description Small cell lung cancer (SCLC) is a highly malignant tumor. The initial treatment of radiotherapy and chemotherapy are more sensitive, high remission rate, but susceptible to drug resistance and relapse after treatment. Although the treatment of lung cancer has undergone enormous changes in recent years, treatment for relapsed SCLC is still a difficult problem in clinical field. In view of the serious resistance of recurrent SCLC to the existing chemotherapeutic drugs, the research on recurrent SCLC around the world is focused on the clinical trial of new drug development, optimization of chemotherapy regimen and target drug development. This paper summarize and estimate studies and literature reports of chemotherapy and precision therapy for relapsed SCLC, hopefully it could help clinicians treat relapsed SCLC and give us clinical research direction for relapsed SCLC in the future.
format Online
Article
Text
id pubmed-5973303
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59733032018-07-06 复发性小细胞肺癌治疗进展 Zhongguo Fei Ai Za Zhi 综述 Small cell lung cancer (SCLC) is a highly malignant tumor. The initial treatment of radiotherapy and chemotherapy are more sensitive, high remission rate, but susceptible to drug resistance and relapse after treatment. Although the treatment of lung cancer has undergone enormous changes in recent years, treatment for relapsed SCLC is still a difficult problem in clinical field. In view of the serious resistance of recurrent SCLC to the existing chemotherapeutic drugs, the research on recurrent SCLC around the world is focused on the clinical trial of new drug development, optimization of chemotherapy regimen and target drug development. This paper summarize and estimate studies and literature reports of chemotherapy and precision therapy for relapsed SCLC, hopefully it could help clinicians treat relapsed SCLC and give us clinical research direction for relapsed SCLC in the future. 中国肺癌杂志编辑部 2017-03-20 /pmc/articles/PMC5973303/ /pubmed/28302222 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.03.08 Text en 版权所有©《中国肺癌杂志》编辑部2017 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
复发性小细胞肺癌治疗进展
title 复发性小细胞肺癌治疗进展
title_full 复发性小细胞肺癌治疗进展
title_fullStr 复发性小细胞肺癌治疗进展
title_full_unstemmed 复发性小细胞肺癌治疗进展
title_short 复发性小细胞肺癌治疗进展
title_sort 复发性小细胞肺癌治疗进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973303/
https://www.ncbi.nlm.nih.gov/pubmed/28302222
http://dx.doi.org/10.3779/j.issn.1009-3419.2017.03.08
work_keys_str_mv AT fùfāxìngxiǎoxìbāofèiáizhìliáojìnzhǎn
AT fùfāxìngxiǎoxìbāofèiáizhìliáojìnzhǎn
AT fùfāxìngxiǎoxìbāofèiáizhìliáojìnzhǎn